Literature DB >> 6511851

Determination of ethylenediamineplatinum(II) malonate in infusion fluids, human plasma and urine by high-performance liquid chromatography.

W J van der Vijgh, F Elferink, G J Postma, J B Vermorken, H M Pinedo.   

Abstract

A selective and convenient high-performance liquid chromatographic assay was developed for ethylenediamineplatinum(II) malonate (JM-40) in plasma ultrafiltrate and urine. A mu Porasil silica column (30 cm) was used with acetonitrile-water (90:10, v/v) as the mobile phase and the elution of compounds was monitored by ultraviolet absorbance at 214 nm. A linear dynamic range of at least three decades (1-1000 micrograms/ml) was achieved. The detection limit in plasma ultrafiltrate was 0.35 micrograms/ml. The stability of JM-40 was determined in 0.9% sodium chloride, 5% glucose, plasma ultrafiltrate and urine. More stable drug solutions were obtained with 5% glucose than with 0.9% sodium chloride. JM-40 was also determined in plasma ultrafiltrate and urine samples of one patient receiving short-term infusions of the drug. In plasma ultrafiltrate unmetabolized JM-40 was detected during the first 5 h after administration and had a half-life of 21.3 +/- 1.6 min. The parent drug was excreted in the urine in rapidly decreasing amounts. Eighteen per cent of the dose was recovered as unmetabolized drug during the first 6 h.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6511851     DOI: 10.1016/0378-4347(84)80098-5

Source DB:  PubMed          Journal:  J Chromatogr


  5 in total

Review 1.  Stability of solutions of antineoplastic agents during preparation and storage for in vitro assays. III. Antimetabolites, tubulin-binding agents, platinum drugs, amsacrine, L-asparaginase, interferons, steroids and other miscellaneous antitumor agents.

Authors:  A G Bosanquet
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

2.  Protein binding of five platinum compounds. Comparison of two ultrafiltration systems.

Authors:  W J van der Vijgh; I Klein
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

Review 3.  Platinum antitumour agents: a review of (bio)analysis.

Authors:  T J Hodes; W J Underberg; G Los; J H Beijnen
Journal:  Pharm Weekbl Sci       Date:  1992-06-19

4.  Stability of the new anticancer platinum analogue 1,2-diaminomethyl-cyclobutane-platinum(II)-lactate (lobaplatin; D19466) in intravenous solutions.

Authors:  H J Guchelaar; D R Uges; P Aulenbacher; E G de Vries; N H Mulder
Journal:  Pharm Res       Date:  1992-06       Impact factor: 4.200

5.  Pharmacokinetics of ethylenediaminemalonatoplatinum(II) (JM-40) during phase I trial.

Authors:  F Elferink; W J van der Vijgh; W W ten Bokkel Huinink; J B Vermorken; I Klein; B Winograd; M K Knobf; G Simonetti; H E Gall; J G McVie
Journal:  Br J Cancer       Date:  1987-10       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.